Story Submitted
Aurobindo Pharma Q1FY23 results profitability affected due to higher input costs univest.in
Aurobindo Pharma announced their Q1FY23 results on 12th August 2022, where they reported lower than expected profits due to cost headwinds creating margins pressure. Geographically speaking, US business grew well YoY, while EU business remained sluggish. The Aurobindo Stock has experienced a big correction on the technical standpoint since the beginning of 2022. It didn’t make any significant moves on either side after the release of…